文献速递心力衰竭与心肌病心律失常

超越射血分数:非缺血性扩张型心肌病心律失常风险分层

Arrhythmic risk stratification in non-ischaemic dilated cardiomyopathy beyond ejection fraction.
PubMed 文献 · Heart · 2020-01-21

该综述指出,尽管非缺血性扩张型心肌病(NICM)患者的心律失常事件因循证治疗而减少,但仅凭左心室射血分数(LVEF)进行植入式心律转复除颤器(ICD)指征评估已显不足。文章汇总了心电图、超声心动图、影像学及遗传标志物等多参数风险分层依据,强调整合心脏磁共振(尤其晚期钆增强)与特定基因信息(如LMNA、PLN、FLNC突变)对完善当前风险分层至关重要,并提出需兼顾心律失常风险与左室逆重构预测的动态多参数评估思路。

要点

  • NICM心律失常风险分层不能仅依赖LVEF,需多参数综合评估。
  • 心脏磁共振晚期钆增强与特定基因突变(LMNA、PLN、FLNC)是风险分层关键。
  • 未来需整合心律失常与心衰事件竞争风险及左室逆重构预测。

核心结论

  • 单纯基于LVEF的ICD植入指征对NICM患者心律失常风险分层不足,需转向多参数评估。
  • 整合心脏磁共振晚期钆增强与特定基因信息是完善当前风险分层的核心。
  • 兼顾心律失常风险与左室逆重构预测的动态评估可能有助于NICM的多参数风险分层。

研究设计与样本

  • 综述性文章,未报告系统检索范围与样本量。

主要发现

  • 近二十年来NICM患者心脏性猝死与心律失常相关事件因循证药物与非药物治疗显著减少。
  • 心电图、超声心动图、影像学及遗传标志物等多参数对NICM心律失常风险分层至关重要。
  • 心脏磁共振参数(尤其晚期钆增强)与特定基因信息(LMNA、PLN、FLNC突变)的整合被认为是完善当前风险分层的基础。

关键数值与推荐

  • 基于左心室射血分数(LVEF)的简单指征被认为不足以进行NICM心律失常风险分层。
  • 特定基因信息包括LMNA、PLN、FLNC突变的存在。
  • 心脏磁共振参数主要指晚期钆增强(LGE)。

临床怎么用

  • 对NICM患者评估心律失常风险时,不应仅依据LVEF,应综合心电图、超声、心脏磁共振及遗传信息。
  • 考虑将心脏磁共振晚期钆增强与特定基因突变(LMNA、PLN、FLNC)纳入ICD植入决策的多参数评估。
  • 随访中可同时关注心律失常风险与左室逆重构预测,以动态评估风险。

局限性

  • 本文为综述,未提供原始研究数据或系统评价方法。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Sudden cardiac death and arrhythmia-related events in patients with non-ischaemic dilated cardiomyopathy (NICM) have been significantly reduced over the last couple of decades as a result of evidence-based pharmacological and non-pharmacological therapeutic strategies. Nevertheless, the arrhythmic stratification in patients with NICM remains extremely challenging, and the simple indication based on left ventricular ejection fraction appears to be insufficient. Therefore, clinicians need to go beyond the current criteria for implantable cardioverter-defibrillator implantation in the direction of a multiparametric evaluation of arrhythmic risk. Several parameters for arrhythmic risk stratification, ranging from electrocardiographic, echocardiographic, imaging-derived and genetic markers, are crucial for proper arrhythmic risk stratification and a multiparametric evaluation of risk in patients with NICM. In particular, integration of cardiac magnetic resonance parameters (mostly late gadolinium enhancement) and specific genetic information (ie, presence of LMNA, PLN, FLNC mutations) appears fundamental for proper implementation of the current arrhythmic risk stratification. Finally, a novel approach focused on both arrhythmic risk and prediction of left ventricular reverse remodelling during follow-up might be useful for effective multiparametric and dynamic arrhythmic risk stratification in NICM. In the future, a complete and integrated evaluation might be mandatory to implement arrhythmic risk prediction in patients with NICM and to discriminate the competing risk between heart failure-related events and life-threatening arrhythmias.

来源:Heart,查看原文。版权归原作者所有。

引用

  1. Cannatà A, De Angelis G, Boscutti A, et al. Arrhythmic risk stratification in non-ischaemic dilated cardiomyopathy beyond ejection fraction. Heart. 2020. PMID: 31964657. doi:10.1136/heartjnl-2019-315942

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。